1187-11-7

Usage

Uses

Used in Polymer Chemistry:
Acetylmalononitrile is used as a rate accelerator for TEMPO-mediated living free radical polymerization (LFRP) to enhance the reaction rate and improve the efficiency of the polymerization process. Its ability to increase the rate of LFRP makes it a valuable additive in the synthesis of various polymers with controlled molecular structures and properties.
Used in Material Science:
In the field of material science, Acetylmalononitrile can be utilized as a component in the development of novel materials with specific properties. Its role in accelerating the polymerization process can lead to the creation of materials with tailored characteristics, such as improved mechanical strength, thermal stability, or chemical resistance, depending on the desired application.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, Acetylmalononitrile may also find applications in the pharmaceutical industry, potentially as an intermediate in the synthesis of various drugs or as a component in drug delivery systems. Its unique chemical properties could be harnessed to develop new therapeutic agents or improve the efficacy of existing ones.

InChI:InChI=1/C5H4N2O/c1-4(8)5(2-6)3-7/h5H,1H3

Upstream product

• 75-36-5 acetyl chloride 
• 109-77-3 malononitrile 

Downstream Products

• 5346-56-5 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile 
• 54820-92-7 1,3-dimethyl-5-amino-1H-pyrazole-4-carbonitrile 
• 5453-07-6 5-amino-3-methyl-1H-pyrazole-4-carbonitrile 
• 87412-84-8 4-amino-3-methyl-1-phenylpyrazolo<3,4-d>pyrimidine 
• 5346-58-7 4-amino-1,3-dimethyl-1H-pyrazolo<3,4-d>pyrimidine 
• 5399-44-0 3-methyl-4-amino-1H-pyrazolo[3,4-d]pyrimidine 
• 5515-16-2 2-(methoxyethylidene)propanedinitrile 

Relevant academic research and scientific papers

Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and in Vivo Biological Evaluation for Acute Lung Injury

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is one of the most common complications in COVID-19. Elastase has been recognized as an important target to prevent ALI/ARDS in the patient of COVID-19. Cyclotheonellazole A (CTL-A) is a nat

1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for phospholipase D

Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular molecules. Phospholipase D is a target to modulate cancer-cell invasiveness. This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1. Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the molecules presented here exhibited inhibition of phospholipase D activity (IC50) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4PC and phospholipid vesicles and micelles. The data strongly indicate that these inhibitory molecules directly block enzyme/vesicle substrate binding. Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment. This study reports synthesis of a new class of PLD inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules exhibited inhibition of human recombinant PLD activity (IC 50) in the low-nanomolar to low-micromolar range with monomeric substrate diC4PC and phospholipid vesicles and micelles. Preliminary activity studies using recombinant human PLDs in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicates inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment.